The Thrombectomy Devices market was valued at US$ 1,282.07 million in 2018 and it is projected to reach US$ 2,101.29 million by 2027; it is expected to grow at a CAGR of 5.9% from 2019 to 2027.
The Thrombectomy Devices market was valued at US$ 1,282.07 million in 2018 and it is projected to reach US$ 2,101.29 million by 2027; it is expected to grow at a CAGR of 5.9% from 2019 to 2027.
Surgical thrombectomy is a surgery performed for the removal of a blood clot from an artery or vein. The surgery is performed when the blood coagulates and clusters to form a blood clot in the blood vessels. In operation, an incision is made using thrombectomy devices in a blood vessel. The clot is eliminated, and the blood vessel is fixed; it repairs blood flow. Mechanical thrombectomy devices are most widely used for thrombectomy procedures as compared to the other methods. The growth of the Thrombectomy Devices in healthcare market is attributed to the growth of market are elevating incidences of CVDs and neurological diseases, technological advancements, government initiatives towards prevention of diseases and favorable medical reimbursement scenario. However, the growth of market is likely to experience restraining factors such as limited patient awareness related to thrombectomy and lack of trained healthcare professionals.
Request for sample Copy at: https://www.theinsightpartners.com/sample/TIPHE100001313/
Thrombectomy Devices market Segmentation:
- In terms of type, the Thrombectomy Devices in healthcare market is segmented into mechanical thrombectomy devices, aspiration thrombectomy, devices, rheolytic thrombectomy devices and ultrasonic thrombectomy. In 2018, the mechanical thrombectomy devices segment held the largest share of the market. Moreover, mechanical thrombectomy devices segment is expected to register the highest CAGR of 6.4% in the market during the forecast period.
- Based on application, the Thrombectomy Devices in healthcare market is segmented into cardiovascular, peripheral vascular, neurovascular. In 2018, cardiovascular segment held the largest share of the market. However, peripheral vascular segment is expected to grow at the fastest rate during the coming year.
- In terms of end user, the Thrombectomy Devices in healthcare market is segmented into academic & research institutes, hospitals & clinics, ambulatory surgical center. In 2018, hospitals segment held the largest share of the market. Moreover, the hospitals segment is expected to grow at the fastest rate during the coming year.
- The leading companies operating in the thrombectomy devices market include Penumbra, Inc, Edwards Lifesciences Corporation Koninklijke Philips N.V., Teleflex Incorporated, Johnson & Johnson Services, Inc (DePuy Synthes), Argon Medical, Inari Medical, Medtronic, Stryker Corporation, Terumo Corporation among others.
- The market has observed various organic as well as inorganic developments during recent years in the thrombectomy devices market. For instance, in February 2019, Edwards Lifesciences Corporation announced that it has received CE Mark approval for PASCAL transcatheter valve repair system which is used for treatment of patients with mitral regurgitation. The launch has enabled the company to offer better innovative products in the market.
Growing Applications of Thrombectomy Devices in Healthcare to Drive Thrombectomy Devices in Healthcare Market Growth
Neurological diseases are disorders of brain, spine, and the nerves connecting the earlier two as well as supplying oxygenated blood. The neurovascular systems are highly dependent on the continuous supply of oxygen and nutrients supplied by the arteries and veins. Therefore, a defect in the system can impair the function, and it may quickly become a life-threatening issue. Thrombosis has been increasing in diseases such as peripheral vascular, neurovascular, and other diseases. Thrombosis is a biological response that is closely linked to cerebral aneurysms, which are balloon-like dilations of blood vessel walls, caused by the weakening of the wall layers.
The prevalence of cerebral aneurysms has increased excessively across the globe. ~30,000 people in the US suffer from brain aneurysm rupture every year. The brain aneurysm breaks every 18 minutes, and the annual rate of rupture in the US is found close to 8–10 per 100,000 people. Moreover, peripheral vascular diseases (PVD) decrease the blood flow and affect blood vessels outside of the heart and brain, and the most commonly affected parts of the body are legs and feet. This disease—a coronary artery disease—occurs in people facing problems with the arteries, which supply blood to heart.
In cardiology, tissue plasminogen activator (tPA) was the primary method to pharmacologically revascularize patients, and it is still the primary therapy for the treatment of acute ischemic stroke. However, that trend at many centers is changing to a neurovascular interventional approach using thrombectomy catheters for clot removal. It is the only FDAapproved treatment modality for acute ischemic stroke. Many key companies—including Boston Scientific, BTG International Ltd., Medtronic, Teleflex, Penumbra Inc., Spectranetics (acquired by Philips Healthcare in 2017), AngioDynamics Inc., Edwards Lifesciences, Rex Medical, Terumo, Stryker, and Cerenovus—are involved in making these catheters. Penumbra key products, Penumbra JET 7 and JET D reperfusion catheters, deliver the deep vacuum aspiration power of the Penumbra ENGINE.
Purchase a copy of the report @ https://www.theinsightpartners.com/buy/TIPHE100001313/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com